Treatment of osteoporosis with bisphosphonates. Differences by mechanism of action. Data on long-term efficacy and safety;Tratamiento de la osteoporosis con bifosfonatos. Diferencias por mecanismo de acción. Datos de eficacia y seguridad a largo plazo

Medicine

Volumn 10, Issue 60, 2010, Pages 4135-4143

  Moro Alvarez M J ^a   Diaz Curiel M ^b  

^a HOSPITAL CENTRAL DE LA CRUZ ROJA   (Spain)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77956052084     PISSN: 03045412     EISSN: 15788822     Source Type: Journal    
DOI: 10.1016/S0304-5412(10)70173-6     Document Type: Article

References (78)

1. H. Fleisch Biphosphonates: Mechanism of action Endocr Rev 19 1998 80 100
2. S.P. Luckman, D.E. Hughes, F.P. Coxon, R. Graham, G. Russell, and M.J. Rogers Nitrogen containing bisphosphonates inhibit the mevalonate pathway and prevent post translational prenilation of GTP binding proteins, including Ras J Bone Miner Res 13 1998 581 589
3. M. Vitale, T. Di Matola, G. Rossi, C. Laezza, G. Fenzi, and M. Bifulco Prenyltransferase inhibitors induce apoptosis in proliferating thyroid cells through a p53-independent CrmA-sensitive, and caspase-3-like protease-dependent mechanism Endocrinology 140 2 1999 698 704
4. Y. Abe, A. Kawakami, T. Nakashima, E. Ejima, K. Fujiyama, and T. Kiriyama Etidronate inhibits human osteoblast apoptosis by inhibition of pro-apoptotic factor(s) produced by activated T cells J Lab Clin Med 136 5 2000 344 354
5. G.H. Nancollas, R. Tang, R.J. Phipps, Z. Henneman, S. Gulde, and W. Wu Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite Bone 38 5 2006 617 627
6. K.L. Kavanagh, K. Guo, J.E. Dunford, X. Wu, S. Knapp, and F.H. Ebetino The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs Proc Natl Acad Sci U S A 103 20 2006 7829 7834
7. A. Cranney, G. Guyatt, N. Krolicki, V. Welch, L. Griffith, and J.D. Adachi A meta-analysis of etidronate for the treatment of postmenopausal osteoporosis Osteoporos Int 12 2001 140 151
8. S. Adami, V. Bruni, D. Bianchini, A. Becorpi, P. Lombardi, and C. Campagnoli Prevention of early postmenopausal bone loss with cyclical etidronate J Endocrinol Invest 23 5 2000 310 316
9. K. Kitatani, K. Nakatsuka, H. Naka, T. Miki, H. Morii, and Y. Nishizawa Clinical usefulness of measurements of urinary deoxypyridinoline (DPD) in patients with postmenopausal osteoporosis receiving intermittent cyclical etidronate: advantage of free form of DPD over total DPD in predicting treatment efficacy J Bone Miner Metab 21 4 2003 217 224
10. S.L. Greenspan, D.L. Schneider, M.R. McLung, P.D. Miller, T.J. Schnitzer, and R. Bonin Alendronate improves bone mineral density in elderly women with osteoporosis residing in long-term care facilities Ann Intern Med 136 2002 742 746
11. H.G. Bone, D. Hosking, J.P. Devogelaer, J.R. Tucci, R.D. Emkey, and R.P. Tonino Ten years' experience with alendronate for osteoporosis in postmenopausal women N Engl J Med 350 12 2004 1189 1199
12. T. Schnitzer, H.G. Bone, G. Crepaldi, S. Adami, M. McClung, and D. Kiel Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group Aging (Milano) 12 2000 1 12
13. R. Rizzoli, S.L. Greenspan, G. Bone 3rd, T.J. Schnitzer, N.B. Watts, and S. Adami Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis J Bone Miner Res 17 11 2002 1988 1996
14. M.M. Luckey, N. Gilchrist, H.G. Bone, M.W. Davie, T.J. de Villiers, and M. Wu Therapeutic equivalence of alendronate 35 milligrams once weekly and 5 milligrams daily in the prevention of postmenopausal osteoporosis Obstet Gynecol 101 2003 711 721
15. H.G. Bone, R.W. Downs Jr, J.R. Tucci, S.T. Harris, and R.S. Weinstein Dose-response relationships for alendronate treatment in osteoporotic elderly women. Alendronate Elderly Osteoporosis Study Centers J Clin Endocrinol Metab 82 1997 265 274
16. Y.Z. Bagger, L.B. Tanko, P. Alexandersen, P. Ravn, and C. Christiansen Alendronate has a residual effect on bone mass in postmenopausal Danish women up to 7 years after treatment withdrawal Bone 33 3 2003 301 307
17. K.E. Ensrud, E.L. Barrett-Connor, A. Schwartz, A.C. Santora, D.C. Bauer, and S. Suryawanshi Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension J Bone Miner Res 19 8 2004 1259 1269
18. N.H. Bell, J.P. Bilezikian, H.G. Bone 3rd, A. Kaur, A. Maragoto, and A.C. Santora Alendronate increases bone mass and reduces bone markers in postmenopausal African-American women J Clin Endocrinol Metab 87 6 2002 2792 2797
19. L.O. Chailurkit, W. Jongjaroenprasert, S. Rungbunnapun, B. Ongphiphadhanakul, S. Sae-tung, and R. Rajatanavin Effect of alendronate on bone mineral density and bone turnover in Thai postmenopausal osteoporosis J Bone Miner Metab 21 6 2003 421 427
20. D.M. Black, D.E. Thompson, D.C. Bauer, K. Ensrud, T. Musliner, and M.C. Hochberg Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group J Clin Endocrinol Metab 85 11 2000 4118 4124
21. S.A. Quandt, D.E. Thompson, D.L. Schneider, M.C. Nevitt, D.M. Black Fracture Intervention Trial Research Group Effect of alendronate on vertebral fracture risk in women with bone mineral density T scores of-1.6 to -2.5 at the femoral neck: the Fracture Intervention Trial Mayo Clin Proc 80 3 2005 343 349
22. A. Cranney, G. Wells, A. Willan, L. Griffith, N. Zytaruk, and V. Robinson Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women Endocr Rev 23 4 2002 508 516
23. S. Boonen, R.F. Laan, I.P. Barton, and N.B. Watts Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studies Osteoporos Int 16 10 2005 1291 1298
24. S.E. Papapoulos, S.A. Quandt, U.A. Liberman, M.C. Hochberg, and D.E. Thompson Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women Osteoporos Int 16 5 2005 468 474
25. K.G. Saag, R. Emkey, T.J. Schnitzer, J.P. Brown, F. Hawkins, and S. Goemaere Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group N Engl J Med 339 5 1998 292 299
26. R. Emkey, P.D. Delmas, S. Goemaere, U.A. Liberman, P.E. Poubelle, and A.G. Daifotis Changes in bone mineral density following discontinuation or continuation of alendronate therapy in glucocorticoid-treated patients: a retrospective, observational study Arthritis Rheum 48 4 2003 1102 1108
27. E. Orwoll, M. Ettinger, S. Weiss, P. Miller, D. Kendler, and J. Graham Alendronate for the treatment of osteoporosis in men N Engl J Med 343 9 2000 604 610
28. J.D. Ringe, H. Faber, and A. Dorst Alendronate treatment of established primary osteoporosis in men: results of a 2-year prospective study J Clin Endocrinol Metab 86 2001 5252 5255
29. J.D. Ringe, A. Dorst, H. Faber, and K. Ibach Alendronate treatment of established primary osteoporosis in men: 3-year results of a prospective, comparative, two-arm study Rheumatol Int 24 2 2004 110 113
30. J.S. Finkelstein, A. Hayes, J.L. Hunzelman, J.J. Wyland, H. Lee, and R.M. Neer The effects of parathyroid hormone, alendronate, or both in men with osteoporosis N Engl J Med 349 13 2003 1216 1226
31. S. Gonnelli, C. Cepollaro, A. Montagnani, D. Bruni, C. Caffarelli, and M. Breschi Alendronate treatment in men with primary osteoporosis: a three-year longitudinal study Calcif Tissue Int 73 2 2003 133 139
32. P.D. Miller, T. Schnitzer, R. Emkey, E. Orwoll, C. Rosen, and M. Ettinger Weekly oral alendronic acid in male osteoporosis Clin Drug Investig 24 6 2004 333 341
33. I. Shimon, V. Eshed, R. Doolman, B.A. Sela, A. Karasik, and I. Vered Alendronate for osteoporosis in men with androgen-repleted hypogonadism Osteoporos Int 16 12 2005 1591 1596
34. I. Fogelman, C. Ribot, R. Smith, D. Ethgen, E. Sod, and J.Y. Reginster Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. BMD-MNStudy Group J Clin Endocrinol Metab 85 5 2000 1895 1900
35. J.P. Brown, D.L. Kendler, M.R. McClung, R.D. Emkey, J.D. Adachi, and M.A. Bolognese The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis Calcif Tissue Int 71 2 2002 103 111
36. S.T. Harris, N.B. Watts, Z. Li, A.A. Chines, D.A. Hanley, and J.P. Brown Two-year efficacy and tolerability of risedronate once a week for the treatment of women with postmenopausal osteoporosis Curr Med Res Opin 20 5 2004 757 764
37. J.Y. Leung, A.Y. Ho, T.P. Ip, G. Lee, and A.W. Kung The efficacy and tolerability of risedronate on bone mineral density and bone turnover markers in osteoporotic Chinese women: a randomized placebo-controlled study Bone 36 2 2005 358 364
38. L. Raisz, J.A. Smith, M. Trahiotis, P. Fall, K. Shoukri, and J. Digennaro Short-term risedronate treatment in postmenopausal women: effects on biochemical markers of bone turnover Osteoporos Int 11 7 2000 615 620
39. S.T. Harris, N.B. Watts, H.K. Genant, C.D. McKeever, T. Hangartner, and M. Keller Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group JAMA 282 1999 1344 1352
40. J. Reginster, H.W. Minne, O.H. Sorensen, M. Hooper, C. Roux, and M.L. Brandi Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group Osteoporos Int 11 1 2000 83 91
41. A. Cranney, J.D. Adachi, G. Guyatt, A. Papaioannou, V.A. Robinson, and B.J. Shea Risedronate for the prevention and treatment of postmenopausal osteoporosis Cochrane Database Syst Rev 1 2007 CD004523
42. A. Cranney, P. Tugwell, J. Adachi, B. Weaver, N. Zytaruk, and A. Papaioannou Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis Endocr Rev 23 4 2002 517 523
43. M.R. McClung, P. Geusens, P.D. Miller, H. Zippel, W.G. Bensen, and C. Roux Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group N Engl J Med 344 5 2001 333 340
44. O.H. Sorensen, G.M. Crawford, H. Mulder, D.J. Hosking, C. Gennari, and D. Mellstrom Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience Bone 32 2 2003 120 126
45. D.D. Mellstrom, O.H. Sorensen, S. Goemaere, C. Roux, T.D. Johnson, and A.A. Chines Seven years of treatment with risedronate in women with postmenopausal osteoporosis Calcif Tissue Int 75 6 2004 462 468
46. S. Wallach, S. Cohen, D.M. Reid, R.A. Hughes, D.J. Hosking, and R.F. Laan Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy Calcif Tissue Int 67 4 2000 277 285
47. D.M. Reid, S. Adami, J.P. Devogelaer, and A.A. Chines Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy Calcif Tissue Int 69 4 2001 242 247
48. D.M. Reid, R.A. Hughes, R.F. Laan, N.A. Sacco-Gibson, D.H. Wenderoth, and S. Adami Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study J Bone Miner Res 15 6 2000 1006 1013
49. R. Eastell, J.P. Devogelaer, N.F. Peel, A.A. Chines, D.E. Bax, and N. Sacco-Gibson Prevention of bone loss with risedronate in glucocorticoid-treated rheumatoid arthritis patients Osteoporos Int 11 4 2000 331 337
50. J.D. Ringe, P. Farahmand, H. Faber, and A. Dorst Sustained efficacy of risedronate in men with primary and secondary osteoporosis: results of a 2-year study Rheumatol Int 29 3 2009 311 315
51. C.H. Chesnut III, A. Skag, C. Christiansen, R. Recker, J.A. Stakkestad, and A. Hoiseth Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis J Bone Miner Res 19 8 2004 1241 1249
52. P.D. Miller, M.R. McClung, L. Macovei, J.A. Stakkestad, M. Luckey, and B. Bonvoisin Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study J Bone Miner Res 20 8 2005 1315 1322
53. P.D. Delmas, R.R. Recker, C.H. Chesnut 3rd, A. Skag, J.A. Stakkestad, and R. Emkey Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study Osteoporos Int 15I 10 2004 792 798
54. L.B. Tanko, U. Mouritzen, H.J. Lehmann, L. Warming, A. Moelgaard, and S. Christgau Oral ibandronate: changes in markers of bone turn-over during adequately dosed continuous and weekly therapy and during different suboptimally dosed treatment regimens Bone 32 6 2003 687 693
55. C.H. Chesnut, M.P. Ettinger, P.D. Miller, D.J. Baylink, R. Emkey, and S.T. Harris Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE Curr Med Res Opin 21 3 2005 391 401
56. S.T. Harris, W.A. Blumentals, and P.D. Miller Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies Curr Med Res Opin 24 1 2008 237 245
57. A. Cranney, G.A. Wells, E. Yetisir, S. Adami, C. Cooper, and P.D. Delmas Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data Osteoporos Int 20 2 2009 291 297
58. J.A. Stakkestad, P. Lakatos, R. Lorenc, F. Sedarati, C. Neate, and J.Y. Reginster Monthly oral ibandronate is effective and well tolerated after 3 years: the MOBILE long-term extension Clin Rheumatol 27 8 2008 955 960
59. O. Lamy, L. Sandini, I. Pache, S. Fatio, J. Burnand, and P. Burckhardt Intravenous ibandronate in men with osteoporosis: an open pilot study over 2 years J Endocrinol Invest 26 8 2003 728 732
60. Orwoll ES, Binkley NC, Lewiecki EM, Gruntmanis U, Fries MA, Dasic G. Efficacy and safety of monthly ibandronate in men with low bone density. Bone. 2010. En prensa.
61. I.R. Reid, J.P. Brown, P. Burckhardt, Z. Horowitz, P. Richardson, and U. Trechsel Intravenous zoledronic acid in postmenopausal women with low bone mineral density NEngl J Med 346 9 2002 653 661
62. D.M. Black, P.D. Delmas, R. Eastell, I.R. Reid, S. Boonen, and J.A. Cauley Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis NEngl J Med 356 18 2007 1809 1822
63. K.W. Lyles, C.S. Colon-Emeric, J.S. Magaziner, J.D. Adachi, C.F. Pieper, and C. Mautalen Zoledronic acid and clinical fractures and mortality after hip fracture NEngl J Med 357 18 2007 1799 1809
64. D.M. Reid, J.P. Devogelaer, K. Saag, C. Roux, C.S. Lau, and J.Y. Reginster Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, dou-ble-blind, double-dummy, randomised controlled trial Lancet 373 9671 2009 1253 1263
65. F. Lanza, B. Sahba, H. Schwartz, S. Winograd, J. Torosis, and H. Quan The upper GI safety and tolerability of oral alendronate at a dose of 70 milligrams once weekly: a placebo-controlled endoscopy study Am J Gastroenterol 97 1 2002 58 64
66. F.L. Lanza, M.F. Rack, Z. Li, S.A. Krajewski, and M.A. Blank Placebo-controlled, randomized, evaluator-blinded endoscopy study of risedronate vs. aspirin in healthy postmenopausal women Aliment Pharmacol Ther 14 12 2000 1663 1670
67. M. Sosa Henríquez, M.J. Gómez de Tejada Romero, J.V. Bagán Sebastián, M. Díaz Curiel, A. Díez Pérez, and E. Jodar-Gimeno Osteonecrosis de los maxilares: Documento de consenso Rev Osteoporos Metab Miner 1 2009 41 51
68. S.R. Heckbert, G. Li, S.R. Cummings, N.L. Smith, and B.M. Psaty Use of alendronate and risk of incident atrial fibrillation in women Arch Intern Med 168 8 2008 826 831
69. Kim SY, Solomon DH. Bisphosphonates and risk of atrial fibrillation: a meta-analysis. ACR/ARHP Scientific Meeting 2009 (November).
70. C.V. Odvina, J.E. Zerwekh, D.S. Rao, N. Maalouf, F.A. Gottschalk, and C.Y. Pak Severely suppressed bone turnover: a potential complication of alendronate therapy J Clin Endocrinol Metab 90 3 2005 1294 1301
71. Breglia MD, Carter JD. Atypical Insufficiency fracture of the tibia associated with long-term bisphosphonate therapy. J Clin Rheumatol. 2010. En prensa.
72. J.P. Schneider Bisphosphonates and low-impact femoral fractures: current evidence on alendronate-fracture risk Geriatrics 64 1 2009 18 23
73. www.cmaj.ca/cgi/content/full/167/10-suppl/s1
74. www.guideline.gov/summary/summary.aspx?ss=15&doc-id=3876&nbr=3085
75. www.nof.org/professionals/cliniciansguide-form.asp
76. www.osteoporosis.org.au/files/research/postmenopausal-oneill-2004.pdf
77. www.seiomm.org/documentos/Rev-Clin-Esp-Guias-SEIOMM.pdf
78. www.sign.ac.uk/guidelines/fulltext/71/index.html